应用[68Ga]Ga-FAPI-04显像早期检测蒽环类药物诱导的心脏毒性
本研究在大鼠模型中探索[68Ga]Ga-FAPI PET/CT早期识别蒽环类药物诱导心脏毒性(AIC)纤维化过程及指导抗纤维化治疗的可行性。结果显示心脏[68Ga]Ga-FAPI-04摄取在3周和6周时显著高于对照组,且早于左室射血分数(LVEF)下降和不可逆纤维化改变;依那普利治疗后摄取降低、心功能改善、心肌纤维化减轻。结论认为该显像可用于AIC活动性心肌纤维化的早期检测和疗效评估。
要点
- 心脏[68Ga]Ga-FAPI-04摄取在AIC大鼠第3周和第6周显著高于对照组,而第3周LVEF尚无显著差异。
- FAP阳性表达自第3周开始增加,早于不可逆纤维化改变检测到的时间。
- 依那普利治疗3周后[68Ga]Ga-FAPI-04积聚减少,心功能改善,心肌纤维化减轻。
核心结论
- [68Ga]Ga-FAPI PET/CT可用于AIC活动性心肌纤维化的早期检测和治疗干预疗效的评估。
- 以[68Ga]Ga-FAPI PET/CT为指导的早期治疗可能减轻蒽环类药物诱导的心肌损伤并改善心脏功能。
研究设计与样本
- 研究采用多柔比星(DOX)每周经血管内给药1次、分别持续1、2、3和6周(2.5 mg/kg/次,第1-4组)诱导AIC大鼠模型,对照组经血管内给予生理盐水。
- 实验组和对照组(n=4)在疾病诱导后接受[68Ga]Ga-FAPI PET/CT显像。
- 第5组和第6组分别接受DOX注射3周和6周,自第3周起接受血管紧张素转换酶(ACE)抑制剂依那普利(20 mg/kg,每日灌胃)治疗,治疗3周后接受超声心动图和[68Ga]Ga-FAPI PET/CT检查。
- 大鼠心脏行苏木精-伊红染色、FAP免疫组化、天狼星红染色和Masson三色染色以观察病理改变和胶原纤维沉积。
- 每周采集大鼠血液,用酶联免疫吸附试验检测血浆心肌肌钙蛋白I、B型利钠肽和血管紧张素II等心肌损伤标志物。
主要发现
- 心脏[68Ga]Ga-FAPI-04摄取在心脏毒性组显著高于对照组:第3周SUVmax为1.21 ± 0.23 vs 0.67 ± 0.01(P < 0.05),第6周SUVmax为1.48 ± 0.28 vs 0.67 ± 0.08(P < 0.001)。
- 第3周时正常大鼠与AIC大鼠的左室射血分数(LVEF)无显著差异。
- FAP阳性表达自第3周开始增加,早于不可逆纤维化改变被检测到的时间,持续至第6周。
- 依那普利治疗3周后,第5组和第6组的[68Ga]Ga-FAPI-04积聚减少:SUVmax分别从1.21 ± 0.23降至0.77 ± 0.08、从1.48 ± 0.28降至1.09 ± 1.06(P < 0.05)。
- 心脏功能得以保留(第3组LVEF为75.7% ± 7.38% vs 第5组74.5% ± 2.45%,P > 0.05)并改善(第4组LVEF为51.6% ± 9.03%,第6组升至65.2% ± 4.27%,P < 0.05),心肌纤维化减轻(第4组为6.5% ± 1.2%,第6组降至4.31% ± 0.37%,P < 0.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Anthracycline-induced cardiotoxicity (AIC), whose major manifestation is diffuse myocardial fibrosis, is an important clinical problem in cancer therapy. Therefore, early identification and treatment are clinically important. This study aims to explore the feasibility of using 68 Ga-labelled fibroblast activation protein (FAP) inhibitor ([68 Ga]Ga-FAPI) positron emission tomography/computed tomography (PET/CT) for the early identification of the fibrotic process and guidance of antifibrosis therapy in AIC. METHODS: An AIC rat model was induced by the intravascular administration of doxorubicin (DOX) once per week for 1, 2, 3 and 6 weeks (2.5 mg/kg/injection, groups 1-4), whereas intravascular saline was administered to control rats. Experimental and control groups (n = 4) underwent [68 Ga]Ga-FAPI PET/CT following disease induction. Groups 5 and 6 received DOX injections for 3 and 6 weeks, treated with angiotensin-converting enzyme (ACE) inhibitor starting at 3 weeks, treated with enalapril (20 mg/kg, gastric gavage) daily and underwent echocardiography and [68 Ga]Ga-FAPI PET/CT at 3 weeks after treatment. Rat hearts were subjected to haematoxylin and eosin staining, FAP immunohistochemistry, Sirius red staining and Masson's trichrome staining to investigate the pathological changes and deposition of collagen fibres. Rat blood was sampled weekly for the enzyme-linked immunosorbent assay of various markers of myocardial injury, such as plasma cardiac troponin I, B-type natriuretic peptide and angiotensin II. RESULTS: [68 Ga]Ga-FAPI-04 uptake by the heart was significantly higher in the cardiotoxicity group than in the control group at weeks 3 (SUVmax: 1.21 ± 0.23 vs 0.67 ± 0.01, P < 0.05) and 6 (SUVmax: 1.48 ± 0.28 vs 0.67 ± 0.08, P < 0.001), whereas left ventricle ejection fraction (LVEF) did not significantly differ between normal and AIC rats at week 3. FAP+ expression began to increase starting at week 3, before irreversible fibrotic changes were detected, until week 6. After 3 weeks of enalapril treatment, [68 Ga]Ga-FAPI-04 accumulation decreased in groups 5 and 6 (SUVmax decreased from 1.21 ± 0.23 to 0.77 ± 0.08 and 1.48 ± 0.28 to 1.09 ± 1.06, P < 0.05). Cardiac function was preserved (LVEF was 75.7% ± 7.38% in group 3 vs 74.5% ± 2.45% in group 5, P > 0.05) and improved (LVEF increased from 51.6% ± 9.03% in group 4 to 65.2% ± 4.27% in group 6, P < 0.05), and myocardial fibrosis attenuated (from 6.5% ± 1.2% in group 4 to 4.31% ± 0.37% in group 6, P < 0.01). CONCLUSION: [68 Ga]Ga-FAPI PET/CT can be used for the early detection of active myocardial fibrosis in AIC and the evaluation of the efficacy of therapeutic interventions. Early treatment guided by [68 Ga]Ga-FAPI PET/CT may reduce anthracycline-induced myocardial injury and improve heart function.
引用
- Wei Z, Xu H, Chen B, et al. Early detection of anthracycline-induced cardiotoxicity using [68 Ga]Ga-FAPI-04 imaging. Eur J Nucl Med Mol Imaging. 2024. PMID: 38491214. doi:10.1007/s00259-024-06673-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。